The pathophysiological and pharmacological basis of current drug treatment of migraine headache

References

• Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41(7), 646–657 (2001).
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF. Migraine in the United States: a review of epidemiology and health care use. Neurology 43(6 Suppl. 3), S6–S10 (1993).
   PubMed Web of Science ®Google Scholar
• Stovner LJ, Hagen K. Prevalence, burden, and cost of headache disorders. Curr. Opin. Neurol. 19(3), 281–285 (2006).
   PubMed Web of Science ®Google Scholar
• Launer LJ, Terwindt GM, Ferrari MD. The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 53(3), 537–542 (1999).
   PubMed Web of Science ®Google Scholar
• Stewart WF, Lipton RB, Celentano DD, Reed ML. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 267(1), 64–69 (1992).
   PubMed Web of Science ®Google Scholar
• Raggi A, Giovannetti AM, Quintas R et al. A systematic review of the psychosocial difficulties relevant to patients with migraine. J. Headache Pain 13(8), 595–606 (2012).
   PubMed Web of Science ®Google Scholar
• Leonardi M, Steiner TJ, Scher AT, Lipton RB. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J. Headache Pain 6(6), 429–440 (2005).
   PubMedGoogle Scholar
• Spierings EL. Pathogenesis of the migraine attack. Clin. J. Pain 19(4), 255–262 (2003).
   PubMed Web of Science ®Google Scholar
• Stovner Lj, Hagen K, Jensen R et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 27(3), 193–210 (2007).
   PubMed Web of Science ®Google Scholar
• Vecchia D, Pietrobon D. Migraine: a disorder of brain excitatory–inhibitory balance? Trends Neurosci. 35(8), 507–520 (2012).
   PubMed Web of Science ®Google Scholar
• de Vries B, Frants RR, Ferrari MD, van den Maagdenberg AM. Molecular genetics of migraine. Hum. Genet. 126(1), 115–132 (2009).
   PubMed Web of Science ®Google Scholar
• Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol. 10(5), 457–470 (2011).
   PubMed Web of Science ®Google Scholar
• HCS-IHC. The Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 24(Suppl. 1), 9–160 (2004).
   PubMedGoogle Scholar
• Aurora SK, Wilkinson F. The brain is hyperexcitable in migraine. Cephalalgia 27(12), 1442–1453 (2007).
   PubMed Web of Science ®Google Scholar
• Hauge AW, Kirchmann M, Olesen J. Characterization of consistent triggers of migraine with aura. Cephalalgia 31(4), 416–438 (2011).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC. History of migraine with aura and cortical spreading depression from 1941 and onwards. Cephalalgia 30(7), 780–792 (2010).
   PubMedGoogle Scholar
• Wolff HG. Headache and Other Head Pain (2nd Edition). Oxford University Press, NY, USA (1963).
   Google Scholar
• Milner PM. Note on a possible correspondence between the scotomas of migraine and spreading depression of Leão. Electroencephalogr. Clin. Neurophysiol. 10(4), 705 (1958).
   PubMedGoogle Scholar
• Moskowitz MA, Macfarlane R. Neurovascular and molecular mechanisms in migraine headaches. Cerebrovasc. Brain Metab. Rev. 5(3), 159–177 (1993).
   PubMedGoogle Scholar
• Reuter U, Sanchez del Rio M, Moskowitz MA. Experimental models of migraine. Funct. Neurol. 15(Suppl. 3), 9–18 (2000).
   PubMed Web of Science ®Google Scholar
• Dalkara T, Nozari A, Moskowitz MA. Migraine aura pathophysiology: the role of blood vessels and microembolisation. Lancet Neurol. 9(3), 309–317 (2010).
   PubMed Web of Science ®Google Scholar
• Sanchez-Del-Rio M, Reuter U, Moskowitz MA. New insights into migraine pathophysiology. Curr. Opin. Neurol. 19(3), 294–298 (2006).
   PubMedGoogle Scholar
• Olesen J, Friberg L, Olsen TS et al. Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann. Neurol. 28(6), 791–798 (1990).
   PubMed Web of Science ®Google Scholar
• Leao AAP. Spreading depression of activity in cerebral cortex. J. Neurophysiol. 7, 359–390 (1944).
   Google Scholar
• Leao AAP, Morison RS. Propagation of spreading cortical depression. J. Neurophysiol. 8, 33–45 (1945).
   Web of Science ®Google Scholar
• Bolay H, Moskowitz MA. The emerging importance of cortical spreading depression in migraine headache. Rev. Neurol. (Paris) 161(6–7), 655–657 (2005).
   PubMed Web of Science ®Google Scholar
• Ayata C. Spreading depression: from serendipity to targeted therapy in migraine prophylaxis. Cephalalgia 29(10), 1095–1114 (2009).
   PubMed Web of Science ®Google Scholar
• Matsuura T, Bures J. The minimum volume of depolarized neural tissue required for triggering cortical spreading depression in rat. Exp. Brain Res. 12(3), 238–249 (1971).
   PubMed Web of Science ®Google Scholar
• Reid KH, Marrannes R, Wauquier A. Spreading depression and central nervous system pharmacology. J. Pharmacol. Methods 19(1), 1–21 (1988).
   PubMedGoogle Scholar
• Dhir A, Lossin C, Rogawski MA. Propofol hemisuccinate suppresses cortical spreading depression. Neurosci. Lett. 514(1), 67–70 (2012).
   PubMed Web of Science ®Google Scholar
• Maranhão-Filho PA, Martins-Ferreira H, Vincent MB, Ribeiro LJ, Novis SA. Sumatriptan blocks spreading depression in isolated chick retina. Cephalalgia 17(8), 822–825 (1997).
   PubMedGoogle Scholar
• Wiedemann M, de Lima VM, Hanke W. Effects of antimigraine drugs on retinal spreading depression. Naunyn Schmiedebergs Arch. Pharmacol. 353(5), 552–556 (1996).
   PubMedGoogle Scholar
• Akerman S, Goadsby PJ. Topiramate inhibits cortical spreading depression in rat and cat: impact in migraine aura. Neuroreport 16(12), 1383–1387 (2005).
   PubMed Web of Science ®Google Scholar
• Ayata C, Jin H, Kudo C, Dalkara T, Moskowitz MA. Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 59(4), 652–661 (2006).
   PubMed Web of Science ®Google Scholar
• Hoffmann U, Dileköz E, Kudo C, Ayata C. Gabapentin suppresses cortical spreading depression susceptibility. J. Cereb. Blood Flow Metab. 30(9), 1588–1592 (2010).
   PubMed Web of Science ®Google Scholar
• Coppola G, Pierelli F, Schoenen J. Is the cerebral cortex hyperexcitable or hyperresponsive in migraine? Cephalalgia 27(12), 1427–1439 (2007).
   PubMed Web of Science ®Google Scholar
• Fumal A, Schoenen J. Current migraine management – patient acceptability and future approaches. Neuropsychiatr. Dis. Treat. 4(6), 1043–1057 (2008).
   PubMedGoogle Scholar
• Di Lorenzo C, Pierelli F, Coppola G et al. Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 72(18), 1588–1594 (2009).
   PubMed Web of Science ®Google Scholar
• Freilinger T, Anttila V, de Vries B et al.; International Headache Genetics Consortium. Genome-wide association analysis identifies susceptibility loci for migraine without aura. Nat. Genet. 44(7), 777–782 (2012).
   PubMed Web of Science ®Google Scholar
• Ophoff RA, Terwindt GM, Vergouwe MN et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 87(3), 543–552 (1996).
   PubMed Web of Science ®Google Scholar
• De Fusco M, Marconi R, Silvestri L et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump α2 subunit associated with familial hemiplegic migraine type 2. Nat. Genet. 33(2), 192–196 (2003).
   PubMed Web of Science ®Google Scholar
• Dichgans M, Freilinger T, Eckstein G et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 366(9483), 371–377 (2005).
   PubMed Web of Science ®Google Scholar
• Rudkjobing LA, Esserlind AL, Olesen J. Future possibilities in migraine genetics. J. Headache Pain 13(7), 505–511 (2012).
   PubMedGoogle Scholar
• Di Lorenzo C, Grieco GS, Santorelli FM. Migraine headache: a review of the molecular genetics of a common disorder. J. Headache Pain 13(7), 571–580 (2012).
   PubMed Web of Science ®Google Scholar
• Geppetti P, Rossi E, Chiarugi A, Benemei S. Antidromic vasodilatation and the migraine mechanism. J. Headache Pain 13(2), 103–111 (2012).
   PubMed Web of Science ®Google Scholar
• Diener HC, Dodick DW, Goadsby PJ, Lipton RB, Olesen J, Silberstein SD. Chronic migraine – classification, characteristics and treatment. Nat. Rev. Neurol. 8(3), 162–171 (2011).
   Google Scholar
• Mannix LK. Management of menstrual migraine. Neurologist 9(4), 207–213 (2003).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Goldberg J. Menstrually related migraine: breaking the cycle in your clinical practice. J. Reprod. Med. 52(10), 888–895 (2007).
   PubMedGoogle Scholar
• Nappi RE, Nappi G. Neuroendocrine aspects of migraine in women. Gynecol. Endocrinol. 28(Suppl. 1), 37–41 (2012).
   PubMed Web of Science ®Google Scholar
• Allais G, Castagnoli Gabellari I, Rolando S, Benedetto C. Evaluation of the use of sumatriptan–naproxen sodium for menstrual migraine and dysmenorrhea. Expert Rev. Neurother. 11(10), 1383–1387 (2011).
   PubMed Web of Science ®Google Scholar
• Fox AW, Davis RL. Migraine chronobiology. Headache 38(6), 436–441 (1998).
   PubMed Web of Science ®Google Scholar
• MacGregor EA. Menstrual migraine. Curr. Opin. Neurol. 21(3), 309–315 (2008).
   PubMedGoogle Scholar
• MacGregor EA. Prevention and treatment of menstrual migraine. Drugs 70(14), 1799–1818 (2010).
   PubMed Web of Science ®Google Scholar
• Welch KM. Migraine and ovarian steroid hormones. Cephalalgia 17(Suppl. 20), 12–16 (1997).
   PubMedGoogle Scholar
• Massiou H, Jamin C, Hinzelin G, Bidaut-Mazel C; French Naramig Collaborative Study Group. Efficacy of oral naratriptan in the treatment of menstrually related migraine. Eur. J. Neurol. 12(10), 774–781 (2005).
   PubMed Web of Science ®Google Scholar
• Brandes JL, Poole Ac, Kallela M et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. Cephalalgia 29(11), 1133–1148 (2009).
   PubMed Web of Science ®Google Scholar
• Savi L, Omboni S, Lisotto C et al. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study versus rizatriptan. J. Headache Pain 12(6), 609–615 (2011).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. Neurology 63(2), 261–269 (2004).
   PubMed Web of Science ®Google Scholar
• Aukerman G, Knutson D, Miser WF; Department of Family Medicine, Ohio State University College of Medicine and Public Health, Columbus, Ohio. Management of the acute migraine headache. Am. Fam. Physician 66(11), 2123–2130 (2002).
   PubMedGoogle Scholar
• Ashkenazi A, Silberstein SD. The evolving management of migraine. Curr. Opin. Neurol. 16(3), 341–345 (2003).
   PubMedGoogle Scholar
• Rapoport AM. Acute and prophylactic treatments for migraine: present and future. Neurol. Sci. 29(Suppl. 1), S110–S122 (2008).
   Google Scholar
• DeMaagd G. Migraine headache: the pharmacist and the role of OTC medications. Pharmacy Times, 3–11 (2007).
   Google Scholar
• No authors listed. Drugs for migraine. Treatment Guidelines from the Medical Letter. 6(67), 17–22 (2008).
   PubMedGoogle Scholar
• Snow V, Weiss K, Wall EM, Mottur-Pilson C; American Academy of Family Physicians; American College of Physicians–American Society of Internal Medicine. Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann. Intern. Med. 137(10), 840–849 (2002).
   PubMed Web of Science ®Google Scholar
• Sander-Bush E, Mayer SE. 5-HT-receptor agonists and migraine. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics (11th Edition). Brunton LL, Lazo JS, Parker KL (Eds). McGraw-Hill, NY, USA, 306–310 (2006).
   Google Scholar
• Tfelt-Hansen PC, Koehler PJ. History of the use of ergotamine and dihydroergotamine in migraine from 1906 and onward. Cephalalgia 28(8), 877–886 (2008).
   PubMed Web of Science ®Google Scholar
• Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 46(Suppl. 4), S171–S181 (2006).
   PubMed Web of Science ®Google Scholar
• Swidan SZ, Lake AE 3rd, Saper JR. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache. Curr. Pain Headache Rep. 9(1), 65–70 (2005).
   PubMedGoogle Scholar
• Carleton SC, Shesser RF, Pietrzak MP et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann. Emerg. Med. 32(2), 129–138 (1998).
   PubMedGoogle Scholar
• Schaerlinger B, Hickel P, Etienne N, Guesnier L, Maroteaux L. Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy. Br. J. Pharmacol. 140(2), 277–284 (2003).
   PubMed Web of Science ®Google Scholar
• Treves TA, Kuritzky A, Hering R, Korczyn AD. Dihydroergotamine nasal spray in the treatment of acute migraine. Headache 38(8), 614–617 (1998).
   PubMed Web of Science ®Google Scholar
• Boureau F, Kappos L, Schoenen J, Esperanca P, Ashford E. A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine. Int. J. Clin. Pract. 54(5), 281–286 (2000).
   PubMed Web of Science ®Google Scholar
• Young WB. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives. Headache 37(Suppl. 1), S42–S45 (1997).
   Google Scholar
• Morren JA, Galvez-Jimenez N. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy? Expert Opin. Pharmacother. 11(18), 3085–3093 (2010).
   PubMed Web of Science ®Google Scholar
• Aurora SK, Silberstein SD, Kori SH et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 51(4), 507–517 (2011).
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358(9294), 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Brandes JL, Cady RK, Freitag FG et al. Needle-free subcutaneous sumatriptan (Sumavel DosePro): bioequivalence and ease of use. Headache 49(10), 1435–1444 (2009).
   PubMed Web of Science ®Google Scholar
• Frampton JE. Needle-free subcutaneous sumatriptan: in the acute treatment of migraine attacks or cluster headache episodes. CNS Drugs 25(11), 983–994 (2011).
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ferrari MD et al. Prioritizing treatment attributes and their impact on selecting an oral triptan: results from the TRIPSTAR Project. Curr. Pain Headache Rep. 8(6), 435–442 (2004).
   PubMedGoogle Scholar
• Cortelli P, Allais G, Tullo V et al. Frovatriptan versus other triptans in the acute treatment of migraine: pooled analysis of three double-blind, randomized, cross-over, multicenter, Italian studies. Neurol. Sci. 32(Suppl. 1), S95–S98 (2011).
   Web of Science ®Google Scholar
• Chen LC, Ashcroft DM. Meta-analysis of the efficacy and safety of zolmitriptan in the acute treatment of migraine. Headache 48(2), 236–247 (2008).
   PubMedGoogle Scholar
• Lanteri-Minet M, Díaz-Insa S, Leone M, Vila C, Clissold SP; START Study. Efficacy of almotriptan in early intervention for treatment of acute migraine in a primary care setting: the START study. Int. J. Clin. Pract. 64(7), 936–943 (2010).
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen PC. Published and not fully published double-blind, randomised, controlled trials with oral naratriptan in the treatment of migraine: a review based on the GSK Trial Register. J. Headache Pain 12(4), 399–403 (2011).
   PubMed Web of Science ®Google Scholar
• Casolla B, Lionetto L, Candela S et al. Treatment of perimenstrual migraine with triptans: an update. Curr. Pain Headache Rep. 16(5), 445–451 (2012).
   PubMed Web of Science ®Google Scholar
• Allais G, Tullo V, Benedetto C, Zava D, Omboni S, Bussone G. Efficacy of frovatriptan in the acute treatment of menstrually related migraine: analysis of a double-blind, randomized, multicenter, Italian, comparative study versus zolmitriptan. Neurol. Sci. 32(Suppl. 1), S99–S104 (2011).
   PubMed Web of Science ®Google Scholar
• Bigal ME, Ferrari M, Silberstein SD, Lipton RB, Goadsby PJ. Migraine in the triptan era: lessons from epidemiology, pathophysiology, and clinical science. Headache 49(Suppl. 1), S21–S33 (2009).
   PubMed Web of Science ®Google Scholar
• Evans RW, Tepper SJ, Shapiro RE, Sun-Edelstein C, Tietjen GE. The FDA alert on serotonin syndrome with use of triptans combined with selective serotonin reuptake inhibitors or selective serotonin–norepinephrine reuptake inhibitors: American Headache Society position paper. Headache 50(6), 1089–1099 (2010).
   PubMed Web of Science ®Google Scholar
• Schürks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Curr. Treat. Options Neurol. 10(1), 20–29 (2008).
   PubMed Web of Science ®Google Scholar
• Limmroth V, Michel MC. The prevention of migraine: a critical review with special emphasis on β-adrenoceptor blockers. Br. J. Clin. Pharmacol. 52(3), 237–243 (2001).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Lipton RB, Dodick DW et al.; Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache 47(2), 170–180 (2007).
   PubMed Web of Science ®Google Scholar
• Galletti F, Cupini LM, Corbelli I, Calabresi P, Sarchielli P. Pathophysiological basis of migraine prophylaxis. Prog. Neurobiol. 89(2), 176–192 (2009).
   PubMed Web of Science ®Google Scholar
• Togha M, Mansoureh T, Rahmat Jirde M et al. Cinnarizine in refractory migraine prophylaxis: efficacy and tolerability. A comparison with sodium valproate. J. Headache Pain 9(2), 77–82 (2008).
   PubMed Web of Science ®Google Scholar
• Lionetto L, Negro A, Palmisani S et al. Emerging treatment for chronic migraine and refractory chronic migraine. Expert Opin. Emerg. Drugs 17(3), 393–406 (2012).
   PubMed Web of Science ®Google Scholar
• Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a meta-analytic review. Headache 31(5), 333–340 (1991).
   PubMed Web of Science ®Google Scholar
• Carroll JD, Reidy M, Savundra PA, Cleave N, McAinsh J. Long-acting propranolol in the prophylaxis of migraine: a comparative study of two doses. Cephalalgia 10(2), 101–105 (1990).
   PubMedGoogle Scholar
• Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78(17), 1337–1345 (2012).
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Topiramate in migraine prevention: evidence-based medicine from clinical trials. Neurol. Sci. 25(Suppl. 3), S244–S245 (2004).
   Web of Science ®Google Scholar
• Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J. Neurol. Neurosurg. Psychiatry 76(12), 1730–1732 (2008).
   Google Scholar
• Mathew NT, Rapoport A, Saper J et al. Efficacy of gabapentin in migraine prophylaxis. Headache 41(2), 119–128 (2001).
   PubMed Web of Science ®Google Scholar
• Apostol G, Lewis DW, Laforet GA et al. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study. Headache 49(1), 45–53 (2009).
   PubMed Web of Science ®Google Scholar
• Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 322(7277), 19–22 (2001).
   PubMed Web of Science ®Google Scholar
• Gales BJ, Bailey EK, Reed AN, Gales MA. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for the prevention of migraines. Ann. Pharmacother. 44(2), 360–366 (2010).
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E; Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78(17), 1337–1345 (2012).
   PubMed Web of Science ®Google Scholar
• Luo N, Di W, Zhang A et al. A randomized, one-year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Med. 13(1), 80–86 (2012).
   PubMed Web of Science ®Google Scholar
• Taylor FR. Nutraceuticals and headache: the biological basis. Headache 51(3), 484–501 (2011).
   PubMed Web of Science ®Google Scholar
• Slater SK, Nelson TD, Kabbouche MA et al. A randomized, double-blinded, placebo-controlled, crossover, add-on study of coenzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 31(8), 897–905 (2011).
   PubMed Web of Science ®Google Scholar
• Sándor PS, Di Clemente L, Coppola G et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64(4), 713–715 (2005).
   PubMed Web of Science ®Google Scholar
• Magis D, Ambrosini A, Sándor P, Jacquy J, Laloux P, Schoenen J. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache 47(1), 52–57 (2007).
   PubMed Web of Science ®Google Scholar
• Markley HG. CoEnzyme Q10 and riboflavin: the mitochondrial connection. Headache 52(Suppl. 2), 81–87 (2012).
   PubMedGoogle Scholar
• Loder E. Safety of sumatriptan in pregnancy: a review of the data so far. CNS Drugs 17(1), 1–7 (2003).
   PubMed Web of Science ®Google Scholar
• Källén B, Nilsson E, Otterblad Olausson P. Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf. 34(8), 691–703 (2011).
   PubMed Web of Science ®Google Scholar
• Källén B, Lygner PE. Delivery outcome in women who used drugs for migraine during pregnancy with special reference to sumatriptan. Headache 41(4), 351–356 (2001).
   PubMed Web of Science ®Google Scholar
• O’Quinn S, Ephross SA, Williams V, Davis RL, Gutterman DL, Fox AW. Pregnancy and perinatal outcomes in migraineurs using sumatriptan: a prospective study. Arch. Gynecol. Obstet. 263(1–2), 7–12 (1999).
   PubMed Web of Science ®Google Scholar
• Fox AW, Diamond ML, Spierings EL. Migraine during pregnancy: options for therapy. CNS Drugs 19(6), 465–481 (2005).
   PubMed Web of Science ®Google Scholar
• Rogawski MA. Common pathophysiologic mechanisms in migraine and epilepsy. Arch. Neurol. 65(6), 709–714 (2008).
   PubMedGoogle Scholar
• Silberstein SD, for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 55, 754–763 (2000).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. Can we develop neurally acting drugs for the treatment of migraine? Nat. Rev. Drug Discov. 4(9), 741–750 (2005).
   PubMed Web of Science ®Google Scholar
• Negro A, Lionetto L, Simmaco M, Martelletti P. CGRP receptor antagonists: an expanding drug class for acute migraine? Expert Opin. Investig. Drugs 21(6), 807–818 (2012).
   PubMed Web of Science ®Google Scholar
• Buzzi MG, Bonamini M, Moskowitz MA. Neurogenic model of migraine. Cephalalgia 15(4), 277–280 (1995).
   PubMed Web of Science ®Google Scholar
• Olesen J, Ashina M. Emerging migraine treatments and drug targets. Trends Pharmacol. Sci. 32(6), 352–359 (2011).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28(2), 183–187 (1990).
   PubMed Web of Science ®Google Scholar
• Gallai V, Sarchielli P, Floridi A et al. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 15(5), 384–390 (1995).
   PubMed Web of Science ®Google Scholar
• Salvatore CA, Moore EL, Calamari A et al. Pharmacological properties of MK-3207, a potent and orally active calcitonin gene-related peptide receptor antagonist. J. Pharmacol. Exp. Ther. 333, 152–160 (2010).
   PubMed Web of Science ®Google Scholar
• Robertson CE, Garza I. Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine. Neuropsychiatr. Dis. Treat. 8, 35–48 (2012).
   PubMed Web of Science ®Google Scholar
• Dodick D, Gawel M, Agosti R, Miller T, Lei X, Turkel C. OnabotulinumtoxinA for treatment of chronic migraine: Analysis of the 56-week PREEMPT 2 trial. Presented at: 62nd Annual Meeting of the American Academy of Neurology, Toronto, ON, Canada, 10–17 April 2010.
   Google Scholar
• Mathew NT, Jaffri SF. A double-blind comparison of onabotulinumtoxina (Botox) and topiramate (Topamax) for the prophylactic treatment of chronic migraine: a pilot study. Headache 49(10), 1466–1478 (2009).
   PubMed Web of Science ®Google Scholar
• Cady RK, Schreiber CP, Porter JA, Blumenfeld AM, Farmer KU. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine. Headache 51(1), 21–32 (2011).
   PubMed Web of Science ®Google Scholar